Early-stage ALS stem cell study clears initial safety hurdle

A very small, early-stage clinical trial of a new fetal stem cell therapy for amyotrophic lateral sclerosis, better known as Lou Gehrig's disease, is hinting at its potential success. A team of investigators from the University of Michigan and Atlanta's Emory University say that the trial involving five ALS patients has produced no serious side effects. Significantly, the scientific team says, there's no sign that the stem cell therapy is being rejected by the study subjects, who have had the...